Amova Asset Management Americas Inc. Has $12.48 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Amova Asset Management Americas Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 16,171 shares of the biopharmaceutical company’s stock after selling 4,053 shares during the period. Amova Asset Management Americas Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,482,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in REGN. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $1,012,296,000. Dodge & Cox boosted its position in shares of Regeneron Pharmaceuticals by 18.9% during the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after acquiring an additional 724,562 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares in the last quarter. Invesco Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after acquiring an additional 408,649 shares in the last quarter. Finally, Caisse de depot et placement du Quebec boosted its position in shares of Regeneron Pharmaceuticals by 115.4% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company’s stock worth $260,051,000 after acquiring an additional 247,780 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REGN. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Finally, Barclays cut their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $616.18 on Wednesday. The company has a fifty day moving average price of $701.59 and a 200-day moving average price of $741.02. The company has a market capitalization of $65.14 billion, a P/E ratio of 15.01, a PEG ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 52-week low of $503.25 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter last year, the firm earned $8.22 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.